Cambridge Investment Research Advisors
IGC icon

Cambridge Investment Research Advisors’s IGC Pharma IGC Stock Holding History

Cambridge Investment Research Advisors’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,250
Closed -$6K – 2374
2019
Q4 		$6K Sell
10,250
-6,390
-38% -$5.23K ﹤0.01% 2399
2019
Q3 		$16K Hold
16,640
– – ﹤0.01% 2325
2019
Q2 		$27K Buy
16,640
+100
+0.6% +$141 ﹤0.01% 2175
2019
Q1 		$34K Buy
+16,540
New +$37.6K ﹤0.01% 2239
2018
Q4 		– Sell
-11,700
Closed -$75K – 2214
2018
Q3 		$75K Buy
+11,700
New +$12.2K ﹤0.01% 2166

Other funds holding IGC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CFA
Carroll Financial Associates Charlotte, North Carolina $1.88B AUM 20.52% 1-Year Est. Return
DP
Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Cambridge Investment Research Advisors's IGC Position: Q1 2020 in Review

Cambridge Investment Research Advisors sold out of IGC Pharma (IGC) in Q1 2020, closing a stake of 10,250 shares — an estimated $6K sold.

Cambridge Investment Research Advisors first reported a position in IGC in Q3 2018 and held it in 5 quarters. The position peaked at $75K in Q3 2018. 21 funds tracked by Wall St. Rank hold IGC as of Q1 2020.

  • Cambridge Investment Research Advisors reported no remaining IGC Pharma position as of Q1 2020 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 10,250 IGC Pharma shares in Q1 2020, an estimated $6K.
  • Cambridge Investment Research Advisors first reported a position in IGC Pharma in Q3 2018 and held it in 5 quarters.
  • Cambridge Investment Research Advisors's IGC Pharma position peaked at $75K in Q3 2018.
  • 21 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2020.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2020, filed 8 May 2020.